Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for lebrikizumab

  1. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

    Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.

    Technology appraisal guidance
    Published
    10 July 2024
    View recommendations

    Sections for TA986

  2. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221

    In development [GID-TA11183] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development